Literature DB >> 23335517

Current approach to epithelial ovarian cancer based on the concept of cancer stem cells.

B Djordjevic1, S Stojanovic, I Conic, L Jankovic-Velickovic, P Vukomanovic, R Zivadinovic, M Vukadinovic.   

Abstract

Epithelial ovarian cancer (EOC) is the most common ovarian malignancy. EOCs comprise a diverse group of neoplasms, exhibiting a wide range of morphological characteristics, genetic alterations, and biological behaviors. Currently, there is no effective screening for early detection of EOCs and more than two-thirds of EOC patients are diagnosed with advanced stage disease. The major limiting factors in the treatment of EOC patients are recurrence and chemoresistance. Recent studies suggest that EOCs, like other solid tumors, contain distinct populations of cells that are responsible for tumor initiation, maintenance and growth. These cells, termed cancer stem cells (CSCs), display some of the features of normal stem cells and are thought to evade current chemotherapeutic strategies for the treatment of EOCs. Distinguishing CSC-associated antigen profiles may elucidate novel, more sensitive biomarkers for early detection of EOCs and provide molecular targets for the development of new treatment modalities. This review summarizes the current approaches to EOCs based on the concept of CSCs and evaluates their clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23335517

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  5 in total

Review 1.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

Review 2.  Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.

Authors:  Federica Tomao; Anselmo Papa; Luigi Rossi; Martina Strudel; Patrizia Vici; Giuseppe Lo Russo; Silverio Tomao
Journal:  J Exp Clin Cancer Res       Date:  2013-08-01

3.  RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.

Authors:  R R Somasagara; S M Spencer; K Tripathi; D W Clark; C Mani; L Madeira da Silva; J Scalici; H Kothayer; A D Westwell; R P Rocconi; K Palle
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

4.  A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.

Authors:  Vsevolod I Kiselev; Levon A Ashrafyan; Ekaterina L Muyzhnek; Evgeniya V Gerfanova; Irina B Antonova; Olga I Aleshikova; Fazlul H Sarkar
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

5.  Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer.

Authors:  Candace M Howard; Nadim Bou Zgheib; Stephen Bush; Timothy DeEulis; Antonio Cortese; Antonio Mollo; Seth T Lirette; Krista Denning; Jagan Valluri; Pier Paolo Claudio
Journal:  Transl Oncol       Date:  2020-08-28       Impact factor: 4.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.